Macrogol 4000

ApprovedSmall molecule

IIstituto Clinico Humanitas

Macrogol 4000 is one of 55 small molecule programs targeting Cystic Fibrosis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cystic FibrosisTerminated

Chronic ConstipationActive, not recruiting

Cystic FibrosisPhase 2

Terminated

Chronic ConstipationApproved

Active, not recruiting

Competition

Competitive Landscape

386 competitors in Cystic Fibrosis

#DrugCompanyPhaseTrials

Macrogol 4000

IIstituto Clinico Humanitas

Approved

1 2

Onglyza

AstraZeneca

Preclinical

2 3

Calciferol

Alnylam Pharmaceuticals

Preclinical

1 4

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

3 5

Proair HFA

GGlaxo Dba Glaxosmithkline

Preclinical

2 6

Actimmune

HHorizon Therapeutics Ireland DAC

Preclinical

2 7

Aztreonam Lysine

Gilead

Preclinical

5 8

Advil

KKenvue Brands

Preclinical

1 9

Serevent

GGlaxo Dba Glaxosmithkline

Preclinical

1 10

Tums

Otsuka

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic constipation1 trial

Effectiveness & Safety of Promelaxin® Microenemas Against Macrogol 4000 P.O. in Chronic Constipation in Children 6-48 Months

Completed·AAboca Spa Societa' Agricola·Phase 4·NCT02751411·158 enrolled

Efficacy1 trial

Study Comparing the Bowel Cleansing Efficacy of PLENVU® Versus SELG-ESSE® Using a 2-Day Split Dosing Regimen.

Completed·IIstituto Clinico Humanitas·Phase 4·NCT03742232·399 enrolled

Cystic Fibrosis1 trial

Effect of Polyethylene Glycol Treatment on Intestinal Inflammation Associated With Cystic Fibrosis Inchildren

Terminated·UUniversity Hospital, Bordeaux·Phase 2·NCT04458129·23 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Macrogol 4000. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Macrogol 4000 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Macrogol 4000. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Istituto Clinico Humanitas company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: IIstituto Clinico Humanitas

Macrogol 4000

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic constipation1 trial

Efficacy1 trial

Cystic Fibrosis1 trial

References

Drug Info

Quick Facts

Related News